Lotus Pharmaceutical Co (Lotus Pharmaceutical Co) Total Liabilities : $540.58 Mil (As of Mar. 2024)

View and export this data going back to . Start your Free Trial

What is Lotus Pharmaceutical Co Total Liabilities?

Lotus Pharmaceutical Co's Total Liabilities for the quarter that ended in Mar. 2024 was $540.58 Mil.

Lotus Pharmaceutical Co's quarterly Total Liabilities declined from Sep. 2023 ($504.42 Mil) to Dec. 2023 ($501.03 Mil) but then increased from Dec. 2023 ($501.03 Mil) to Mar. 2024 ($540.58 Mil).

Lotus Pharmaceutical Co's annual Total Liabilities increased from Dec. 2021 ($365.91 Mil) to Dec. 2022 ($510.83 Mil) but then declined from Dec. 2022 ($510.83 Mil) to Dec. 2023 ($501.03 Mil).

Lotus Pharmaceutical Co Total Liabilities Historical Data

The historical data trend for Lotus Pharmaceutical Co's Total Liabilities can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Lotus Pharmaceutical Co Total Liabilities Chart

Lotus Pharmaceutical Co Annual Data

Trend

Dec14

Dec15

Dec16

Dec17

Dec18

Dec19

Dec20

Dec21

Dec22

Dec23

Total Liabilities

Get a 7-Day Free Trial

346.22

390.32

365.91

510.83

501.03

Lotus Pharmaceutical Co Quarterly Data
	Jun19	Sep19	Dec19	Mar20	Jun20	Sep20	Dec20	Mar21	Jun21	Sep21	Dec21	Mar22	Jun22	Sep22	Dec22	Mar23	Jun23	Sep23	Dec23	Mar24
Total Liabilities	Get a 7-Day Free Trial															542.58	527.04	504.42	501.03	540.58

Lotus Pharmaceutical Co Total Liabilities Calculation

Total Liabilities are the liabilities that the company has to pay others. It is a part of the balance sheet of a company that shareholders do not own, and would be obligated to pay back if the company liquidated.

Lotus Pharmaceutical Co's Total Liabilities for the fiscal year that ended in Dec. 2023 is calculated as

Total Liabilities	=	Total Current Liabilities	+	Total Noncurrent Liabilities
	=	Total Current Liabilities	+	(Long-Term Debt & Capital Lease Obligation	+	Other Long-Term Liabilities
	=	144.77	+	(310.436	+	30.423
	+	NonCurrent Deferred Liabilities	+	PensionAndRetirementBenefit)
	+	0	+	15.401)
	=	501.03

Total Liabilities	=	Total Assets (A: Dec. 2023 )	-	Total Equity (A: Dec. 2023 )
	=	1055.68	-	554.65
	=	501.03

Lotus Pharmaceutical Co's Total Liabilities for the quarter that ended in Mar. 2024 is calculated as

Total Liabilities	=	Total Current Liabilities	+	Total Noncurrent Liabilities
	=	Total Current Liabilities	+	(Long-Term Debt & Capital Lease Obligation	+	Other Long-Term Liabilities
	=	190.709	+	(304.051	+	29.745
	+	NonCurrent Deferred Liabilities	+	PensionAndRetirementBenefit)
	+	0	+	16.074)
	=	540.58

Total Liabilities	=	Total Assets (Q: Mar. 2024 )	-	Total Equity (Q: Mar. 2024 )
	=	1081.867	-	541.288
	=	540.58

Lotus Pharmaceutical Co Total Liabilities Related Terms

Thank you for viewing the detailed overview of Lotus Pharmaceutical Co's Total Liabilities provided by GuruFocus.com. Please click on the following links to see related term pages.

Lotus Pharmaceutical Co (Lotus Pharmaceutical Co) Business Description

Industry

GURUFOCUS.COM » STOCK LIST » Healthcare » Drug Manufacturers » Lotus Pharmaceutical Co Ltd (OTCPK:LTPCF) » Definitions » Total Liabilities

Comparable Companies

Traded in Other Exchanges

1795:Taiwan

Address

Song Ren Road, 17th Floor, No. 277, Xin Yi District, Taipei, TWN, 110

Website

https://www.lotuspharm.com.tw

Lotus Pharmaceutical Co Ltd is engaged in the healthcare sector. It is engaged in generic drug business segment, which engages mainly in the research and development, manufacturing and sales of generic pharmaceutical products. It has its geographic presence in United States, South Korea and Others.

Lotus Pharmaceutical Co (Lotus Pharmaceutical Co) Headlines

From GuruFocus

LOTUS REPORTS ITS BEST QUARTER EVER WITH THE BIGGEST LAUNCH IN ITS HISTORY

By PRNewswire PRNewswire • 11-11-2022